London
· Delayed Price · Currency is GBP · Price in USD Halozyme Therapeutics Statistics
Total Valuation
LON:0J2O has a market cap or net worth of GBP 5.69 billion. The enterprise value is 6.40 billion.
| Market Cap | 5.69B |
| Enterprise Value | 6.40B |
Important Dates
The next estimated earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -3.56% |
| Shares Change (QoQ) | -0.89% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 122.17M |
Valuation Ratios
The trailing PE ratio is 16.04.
| PE Ratio | 16.04 |
| Forward PE | n/a |
| PS Ratio | 7.02 |
| PB Ratio | 19.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.21 |
| P/OCF Ratio | 14.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.42, with an EV/FCF ratio of 17.10.
| EV / Earnings | 18.03 |
| EV / Sales | 8.40 |
| EV / EBITDA | 13.42 |
| EV / EBIT | 15.46 |
| EV / FCF | 17.10 |
Financial Position
The company has a current ratio of 7.80, with a Debt / Equity ratio of 4.22.
| Current Ratio | 7.80 |
| Quick Ratio | 6.50 |
| Debt / Equity | 4.22 |
| Debt / EBITDA | 2.42 |
| Debt / FCF | 3.28 |
| Interest Coverage | 30.48 |
Financial Efficiency
Return on equity (ROE) is 198.42% and return on invested capital (ROIC) is 19.61%.
| Return on Equity (ROE) | 198.42% |
| Return on Assets (ROA) | 18.16% |
| Return on Invested Capital (ROIC) | 19.61% |
| Return on Capital Employed (ROCE) | 28.66% |
| Revenue Per Employee | 2.32M |
| Profits Per Employee | 1.01M |
| Employee Count | 350 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +57.19% |
| 50-Day Moving Average | 60.55 |
| 200-Day Moving Average | 56.13 |
| Relative Strength Index (RSI) | 52.21 |
| Average Volume (20 Days) | 759 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.61 |
Income Statement
In the last 12 months, LON:0J2O had revenue of GBP 811.01 million and earned 354.73 million in profits. Earnings per share was 2.74.
| Revenue | 811.01M |
| Gross Profit | 620.53M |
| Operating Income | 440.50M |
| Pretax Income | 445.02M |
| Net Income | 354.73M |
| EBITDA | 500.90M |
| EBIT | 440.50M |
| Earnings Per Share (EPS) | 2.74 |
Balance Sheet
The company has 476.13 million in cash and 1.23 billion in debt, giving a net cash position of -751.19 million.
| Cash & Cash Equivalents | 476.13M |
| Total Debt | 1.23B |
| Net Cash | -751.19M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 290.61M |
| Book Value Per Share | 2.36 |
| Working Capital | 755.83M |
Cash Flow
In the last 12 months, operating cash flow was 382.66 million and capital expenditures -8.54 million, giving a free cash flow of 374.12 million.
| Operating Cash Flow | 382.66M |
| Capital Expenditures | -8.54M |
| Free Cash Flow | 374.12M |
| FCF Per Share | n/a |
Margins
Gross margin is 76.51%, with operating and profit margins of 54.32% and 43.74%.
| Gross Margin | 76.51% |
| Operating Margin | 54.32% |
| Pretax Margin | 54.87% |
| Profit Margin | 43.74% |
| EBITDA Margin | 61.76% |
| EBIT Margin | 54.32% |
| FCF Margin | 46.13% |
Dividends & Yields
LON:0J2O does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.56% |
| Shareholder Yield | 3.56% |
| Earnings Yield | 6.23% |
| FCF Yield | 6.57% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0J2O has an Altman Z-Score of 4.31.
| Altman Z-Score | 4.31 |
| Piotroski F-Score | n/a |